Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines
"Medical research has generated a tremendous number of evidence-based interventions, but these are not universally adopted, leading to gaps in care," said Eviva CEO and founder Alex Morozov, a physician-scientist, writer and former pharmaceutical executive. "Our goal is to empower people to make evidence-based decisions. This is more important now than ever. POH was launched to counteract the assault on science and health — and to reach people before deceptive tactics take hold."
Eviva and POH are grounded in three principles:
On Sunday, MSNBC published an op-ed by Morozov, leading vaccinologist Dr. Helen Petousis-Harris and Eviva board member Professor Stephan Lewandowsky.
"Robert F. Kennedy Jr. and others … appear to be orchestrating a strategic attack on aluminum-containing vaccines," the op-ed says.
But the science does not support aluminum as the culprit. In a major new study involving more than 1.2 million children, Danish researchers found no link between aluminum in vaccines and 50 chronic diseases, including autism.
The op-ed warns: "If anti-vaccine activists successfully undermine aluminum-containing vaccines despite research findings like the Danish study, the consequences will be catastrophic. Vaccine-preventable diseases — such as diphtheria, meningitis, hepatitis and cancers of the liver, cervix and penis — will bounce back, causing tremendous death and suffering. And rates of autism will remain unchanged, as they have for decades."
Protecting Our Health is not just a campaign. It is a call to action. By combining evidence, storytelling and community engagement, Eviva and POH seek to undo the damage caused by misinformation and chart a path forward — one rooted in evidence, empowerment and health for all.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 hours ago
- Korea Herald
Medit to Reveal New Medit i900 Mobility, Powered by True Mobility
SEOUL, South Korea, Aug. 1, 2025 /PRNewswire/ -- Medit ( a global leader in digital dentistry, today introduces the Medit i900 Mobility, a next-generation intraoral scanner designed to deliver simplicity and true mobility to clinical workflows. The Medit i900 Mobility is the latest addition to Medit's scanner lineup, thoughtfully designed to move with the pace of everyday dentistry, wherever care happens. At the heart of the experience are four core pillars of mobility: improved clinical efficiency and workflow fluidity optimized for chair-to-chair and room-to-room use, instant usability with lite installation, enhanced patient interaction during the scanning process and a minimal learning curve that makes adoption easy from the first scan. The i900 Mobility transforms how clinicians work, move and connect with patients by combining precision with ease of use. At the core of this experience is Medit Link Express, the company's first iPad-native companion app, designed to simplify scan-and-send workflows through an intuitive, user-friendly interface. With real-time scan viewing and built-in patient engagement, the app transforms the iPad into a seamless bridge between clinician and patient — immediate, effortless and mobile. Purpose-built for flexibility, the i900 Mobility pairs best-in-class software with compact, responsive hardware, ready to support chairside scanning, team collaboration and care beyond the traditional clinic setting. Designed for a new standard of mobility, key highlights of the i900 Mobility include: Together, the i900 Mobility and Medit Link Express redefine what mobility means in dentistry, reshaping how scanning fits into everyday practice. Whether at the chairside, between clinical staff, easily moving between environments, or stepping beyond the traditional clinic, it's a more fluid, responsive way to work. This is scanning, powered by true mobility. Pre-orders for the Medit i900 Mobility open August 1, 2025, with shipping set to begin from September 1, availability may vary by region. Medit Link Express will be available for download from the Apple App Store starting September 1. For more information and updates, visit About Medit Medit is a global provider of 3D intraoral scanners and digital dentistry solutions based on proprietary technology. The company supports collaborative workflows between dental clinics and labs through innovative hardware and software solutions. Headquartered in Seoul, South Korea, since 2000, Medit has a strong global presence through its offices in the Americas and Europe and a distributor network spanning over 100 countries.
Korea Herald
15 hours ago
- Korea Herald
Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer's disease Including 'Neurophet AQUA AD' at AAIC 2025
SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on the 31st that it participated in the Alzheimer's Association International Conference (AAIC 2025), showcasing its flagship brain imaging analysis AI solutions. At the conference, Jake Junkil Been, Co-CEO of Neurophet, delivered a presentation titled "Neurophet in the Era of Paradigm Shift in Alzheimer's Disease: The Journey to IPO and Beyond," introducing the company's vision and roadmap. During the event, Neurophet introduced Neurophet AQUA AD, neuroimaging analysis software designed to monitor the prescription, treatment effects, and side effects of amyloid-targeted therapeutics for Alzheimer's disease. Neurophet AQUA AD quantitatively analyzes MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans, providing precise brain imaging analysis across the entire treatment process involving anti-amyloid antibody therapies. As the pharmaceutical and biotech industries accelerate the development of Alzheimer's disease treatments, the importance of adopting solutions that can precisely manage prescription, therapeutic efficacy, and potential side effects is increasingly coming into focus. Especially with Alzheimer's disease drugs such as Leqembi® (lecanemab) and Kisunla® (donanemab) requiring close monitoring of side effects, global demand and expectations are rising for Neurophet AQUA AD, a solution capable of analyzing brain imaging biomarkers related to adverse effects. At its exhibition booth, Neurophet is showcasing several key products, including Neurophet AQUA AD, Neurophet AQUA—a brain neurodegeneration imaging analysis software—and Neurophet SCALE PET, a quantitative analysis software for PET imaging. Through its participation in AAIC 2025, Neurophet is engaging in partnering efforts with global pharmaceutical companies and potential clients to pursue business development collaborations. The company is also holding meetings with leading Key Opinion Leaders (KOLs) in the field of neurology to highlight the unique strengths of its products and to build strategic collaborative networks. Jake Junkil Been, Co-CEO of Neurophet said that "Neurophet AQUA AD is gaining attention as a collaborative partner among various Korean and international companies in the field of brain imaging biomarkers," adding, "Through our participation in AAIC 2025, we plan to further accelerate global development collaborations for Neurophet AQUA AD and our other key products." AAIC 2025 is an international conference attended by dementia researchers and neurology clinicians, held in Toronto, Canada. This year's conference runs for five days, from July 27 to 31 (local time in Canada). About Neurophet Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system. Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS". Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
Korea Herald
17 hours ago
- Korea Herald
RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference ® 2025 (AAIC ®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other dementias. Highlights include: AAIC is the premier annual conference for presentation and discussion of the latest Alzheimer's and dementia research. This year's conference in Toronto attracted nearly 19,000 registered attendees and included more than 6,400 scientific submissions. Positive Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) Study The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) — a two-year, multi-site clinical trial testing two different lifestyle interventions in a representative population of older adults at risk for cognitive decline and dementia — found that both interventions improved cognition in older adults at risk of cognitive decline. Trial participants in the structured intervention showed greater improvement on global cognition compared to the self-guided intervention, helping to protect against normal age-related decline for up to two years. This means that, relative to the self-guided group, participants in the structured group performed at a level comparable to adults one to nearly two years younger in age — an effect that likely increases resilience against cognitive decline. This extra benefit was similar across all subgroups of U.S. POINTER participants — regardless of sex, ethnicity, genetic risk or heart health (blood pressure, cholesterol, and glucose levels). More than 30% of participants were from groups that have been historically underrepresented in dementia research. Both interventions focused on increasing physical activity, improving nutrition, cognitive and social challenge, and health monitoring. The structured intervention differed from the self-guided intervention in intensity, structure, accountability and the support provided. U.S. POINTER was a large-scale, rigorous, randomized controlled clinical trial. These positive results underscore the message that healthy behavior has a powerful impact on brain health, and encourage us to look at the potential for a combination of a lifestyle program and drug treatment as the next frontier in the fight against cognitive decline and possibly dementia. First Clinical Practice Guideline For Blood Biomarker Tests in Alzheimer's Diagnosis The Alzheimer's Association released its first evidence-based clinical practice guideline (CPG) on the use of blood-based biomarker (BBM) tests at AAIC 2025, a big step toward transforming Alzheimer's diagnosis and management in specialty care settings. The CPG provides rigorous, evidence-based recommendations to help specialist clinicians to use BBM tests more confidently and consistently. The recommendations are aimed at a variety of specialists in settings like neurology, psychiatry, geriatrics and more who diagnose and evaluate cognitive impairment, and are based on a review of available evidence through November 2024. The recommendations suggest that specialists can use BBM tests as a triaging tool in the diagnostic workup of Alzheimer's when they have at least 90% sensitivity and 75% specificity, but a positive triaging test should always be confirmed with more traditional tests like cerebral spinal fluid (CSF) or amyloid positron emission tomography (PET) imaging. The guidelines permit BBM tests with at least 90% sensitivity and 90% specificity to substitute for PET imaging or CSF testing. However, experts caution that many commercially available BBM tests do not yet meet these thresholds. This CPG is part of ALZPro ™ from the Alzheimer's Association, the comprehensive hub of resources and tools for health care professionals and researchers from across disciplines to reduce risk, advance early detection, improve care and expand equitable access for all communities. Combination of Heart-Health Drugs May Also Protect the Brain Taking a combination of common drugs used to treat blood pressure, cholesterol and diabetes may have an added benefit: slower cognitive decline. A study of more than 4,500 older adults showed cognitive test scores similar to people three years younger for participants who took a combination of drugs targeting vascular or metabolic conditions, all of which are known risk factors for dementia. Participants who were on all three of the vascular drugs had the greatest cognitive benefits, and their brains showed fewer signs of Alzheimer's-related changes at autopsy. For those who took only two of the drugs, the most effective pairing for cognitive protection was blood pressure and cholesterol drugs. Lead Pollution Linked to Memory Problems in Older Adults Historic pollution levels from the era of leaded gasoline may be contributing to cognitive issues 50 years later, according to a first-of-its-kind research study. Researchers tracked how exposure to airborne lead from 1960-1974 — when leaded gasoline use was at its highest — impacted brain health later in life. The report estimated that half the U.S. population at that time, more than 170 million people, were exposed to high lead levels in early childhood. The researchers linked the pollution data from the 60s and 70s to a contemporary study conducted between 2012 and 2017. They estimated that 17 to 22% of people living in areas with moderate or high atmospheric lead reported memory issues. While leaded gas has long been phased out, other sources of exposure remain, such as old lead paint, pipes and industrial pollution. Experts say people who had past lead exposure should focus on reducing other risk factors for dementia, including managing high blood pressure, quitting smoking and avoiding social isolation. Lifestyle Change Benefits May Be Strongest for Carriers of Alzheimer's Risk Gene People with a higher genetic risk for Alzheimer's disease may benefit the most from healthy lifestyle interventions like walking, according to a decade of data from three large international studies. Older adults who carry the Alzheimer's risk gene known as APOE4 had higher cognitive benefits from non-drug interventions like exercise, diet and cognitive training than non-carriers. In this study, walking was found to be the most effective healthy habit for slowing down cognitive damage. Like many healthy lifestyle changes, the key was making it a habit, as the study showed that sticking with it for at least two years produced cognitive benefits up to seven years later. Participants in SNAP Food Assistance Program Had Slower Cognitive Decline People who participated in the U.S. Supplemental Nutrition Assistance Program (SNAP) had slower cognitive decline over 10 years than non-participants, according to new research reported at AAIC 2025. Scientists examined data from the nationally representative Health and Retirement Study to compare participants in SNAP, which helps low-income individuals and families buy food, to those who were eligible for the program but didn't participate. They found that SNAP participants had a 0.10% slower decline in overall cognitive function. The difference is significant in the long-term, adding up to an estimated two to three additional years of cognitive health over the study's 10-year period. The study group of 1,131 SNAP participants studied included Whites, Blacks and Hispanics. A control group included 1,216 people who were SNAP-eligible but didn't participate. Researchers found that all groups benefitted, but White participants showed much slower decline than other groups. The findings highlight the potential benefits of food assistance programs to support older adults' cognitive health. Real-World Results for New Alzheimer's Drugs Show Effectiveness, Patient Satisfaction While newly available anti-amyloid Alzheimer's disease drugs have shown effectiveness in tightly controlled clinical trials, they have not been tested in real-world settings until now. Dozens of abstracts reported at AAIC 2025 showed that real world experience with the drugs lecanemab and donanemab produced comparable or better safety to large clinical trials, and patients were satisfied with the results. Researchers tracked the drugs' safety and effectiveness in patients from a variety of settings including U.S. clinics, memory care centers and international universities. Several of the sites are part of the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), which was created by the Alzheimer's Association to collect voluntary real-world data about patients receiving the new treatments, track their long-term health, and share data with scientists and clinicians. New Insights Into Cognitive Health Differences Between Men and Women New research announced at AAIC 2025 sheds light on crucial differences between men and women in risk for Alzheimer's and other diseases that cause dementia. One study found that traumatic brain injuries (TBIs, a well-known risk factor for dementia) were more likely to shrink dementia-related areas of the brain in women than men. Another looked closer at "chemobrain" — declines in thinking and memory reported by about one-third of women receiving breast cancer chemotherapy. Women make up nearly two-thirds of the more than 7 million Americans living with Alzheimer's. The chemobrain study is the first to show that brain changes, inflammation and shrinkage related to the cancer treatment are connected to symptoms like memory lapses and trouble focusing or finding words. The study adds to growing evidence that chemotherapy impacts brain health. The Alzheimer's Association supports research to better understand sex-based differences in cognitive health and prevent negative side effects for chemo patients. Clinicians can learn more about early detection, diagnosis and treatment of dementia using ALZPro, the newly-launched library of online tools and resources for professionals from the Alzheimer's Association. The Alzheimer's Association extends a thank you to the AAIC 2025 Platinum Sponsors: Biogen, Eisai, Lilly and Novo Nordisk. About the Alzheimer's Association International Conference ® (AAIC ®) The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias. As a part of the Alzheimer's Association's research program, AAIC serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial research community. AAIC 2025 home page: AAIC 2025 newsroom: AAIC 2025 hashtag: #AAIC25 About the Alzheimer's Association ® The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia ®. Visit or call 800.272.3900.
